Protagonist Therapeutics
PTGX
92 hedge funds and large institutions have $728M invested in Protagonist Therapeutics in 2020 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 30 increasing their positions, 32 reducing their positions, and 13 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
54% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 13
20% more capital invested
Capital invested by funds: $605M → $728M (+$123M)
8% more funds holding
Funds holding: 85 → 92 (+7)
1.82% more ownership
Funds ownership: 99.47% → 101.29% (+1.8%)
6% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 32
86% less call options, than puts
Call options by funds: $1K | Put options by funds: $7K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$44.5M |
| 2 |
State Street
Boston,
Massachusetts
|
+$14.5M |
| 3 |
BlackRock
New York
|
+$7.78M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$6.02M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$4.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$6.79M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$5.92M |
| 3 |
Goldman Sachs
New York
|
-$5.78M |
| 4 |
D.E. Shaw & Co
New York
|
-$5.35M |
| 5 |
Renaissance Technologies
New York
|
-$3.67M |
PTGX Hedge Fund Activity: Q3 2020 in Review
92 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q3 2020, worth a combined $728M — up 20% from $605M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new PTGX positions and 13 closed out — a net gain of 7 holders — while 30 added to existing stakes and 32 trimmed.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $44.5M. The largest seller was Millennium Management, exiting entirely with an estimated $6.79M sold.
- 92 institutional investors held Protagonist Therapeutics (PTGX) as of Q3 2020, up from 85 in Q2 2020.
- Funds reported $728M of Protagonist Therapeutics stock for Q3 2020, up 20% quarter-over-quarter.
- 20 funds opened new Protagonist Therapeutics positions in Q3 2020 and 13 closed out, a net change of +7 holders.
- The largest Protagonist Therapeutics buyer in Q3 2020 was Consonance Capital Management, an estimated $44.5M added.
- The largest Protagonist Therapeutics seller in Q3 2020 was Millennium Management, an estimated $6.79M sold.
Based on aggregated 13F filings for Q3 2020.